Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
New On The Block Caribou Biosciences, Inc. (NASDAQ: CRBU ), a clinical-stage CRISPR genome-editing biopharmaceutical company, is exploring strategic alternatives to maximize stockholder value and plans to discontinue further development activities for its two allogeneic CAR-T cell therapy programs. The company has hire
Caribou Biosciences announced it will evaluate strategic alternatives and discontinue its vispa-cel and CB-011 allogeneic CAR-T programs. As of June 30, 2026, the company reported $113.8 million in cash, cash equivalents, and marketable securities.
Company to evaluate strategic alternatives to maximize stockholder value ---- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs ---- Cash, cash equivalents, and marketable securities of $113.8 million as of June 30, 2026 --BERKELEY, Calif., Oct. 06, 2026 (G…